Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists
Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy
You may also be interested in...
Massachusetts Medicaid is advising physicians against use of Lilly's atypical antipsychotic Zyprexa (olanzapine) as first-line therapy
Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011